Идёт набор NCT06613100

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

Фаза I С лечением Prostate Cancer

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: Xaluritamig, GnRH Antagonist.
Кому может быть актуально: Состояния в реестре: Prostate Cancer. Базовые параметры: от 18 лет · Мужчины.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: США, Германия
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, and Feasibility of Neoadjuvant Xaluritamig Therapy Prior to Radical Prostatectomy in Subjects With Newly Diagnosed Localized Intermediate or High-Risk Prostate Cancer

Обзор

The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered as monotherapy or in combination with an oral Gonadotropin-releasing Hormone (GnRH) antagonist in the neoadjuvant setting followed by radical prostatectomy, and to evaluate the feasibility and safety of a radical prostatectomy following xaluritamig administered as monotherapy or in combination with an oral GnRH antagonist in the neoadjuvant setting.

Вмешательства

Препарат Xaluritamig
Intravenous (IV) infusion
Препарат GnRH Antagonist
Oral administration

Первичные конечные точки

Number of Participants who Experienced Treatment-emergent Adverse Events [Срок оценки: Up to 45 months]
Number of Participants who Experienced Treatment-related Adverse Events [Срок оценки: Up to 28 months]
Number of Participants who Received Radical Prostatectomy After Completing Xaluritamig Treatment [Срок оценки: Up to 25 months]
Number of Participants who Experienced Complications of Radical Prostatectomy According to Clavien-Dindo Classification [Срок оценки: Up to 28 months]

Вторичные конечные точки (12)

Change in Prostate-specific Antigen (PSA) Levels from Baseline to End of Xaluritamig Treatment [Срок оценки: Up to 25 months]
Prostate Imaging-Reporting and Data System (PI-RADS) Score [Срок оценки: Up to 25 months]
Pathological Complete Response (pCR) Following Radical Prostatectomy [Срок оценки: Up to 25 months]
Minimal Residual Disease (MRD) [Срок оценки: Up to 25 months]
Number of Participants who Rise to PSA ≥ 0.2 ng/mL Post-radical Prostatectomy [Срок оценки: Up to 45 months]
Time to PSA Rise ≥ 0.2 ng/mL Post-radical Prostatectomy [Срок оценки: Up to 45 months]
Undetectable PSA at SFU [Срок оценки: Up to 26 months]
PSA Progression-free Survival [Срок оценки: Up to 45 months]
Maximum Serum Concentration (Cmax) of Xaluritamig [Срок оценки: Up to 45 months]
Time to Maximum Concentration (Tmax) of Xaluritamig [Срок оценки: Up to 45 months]
Area Under the Concentration Time Curve (AUC) Over the Dosing Interval [Срок оценки: Up to 45 months]
Accumulation Following Multiple Dosing [Срок оценки: Up to 45 months]

Критерии участия

Критерии включения

Participants are eligible to be included in the study only if all the following criteria apply:

Participants planned to undergo radical prostatectomy.
Histologically or cytologically confirmed adenocarcinoma of the prostate at initial biopsy, without neuroendocrine differentiation, signet cell, or small cell features. Intermediate- or high-risk localized prostate cancer, defined as:

Gleason score of 4+3 or higher AND initial PSA (iPSA) >10 OR
Clinically advanced (cT3) on Magnetic Resonance Imaging (MRI) obtained within 3 months prior to screening AND/OR
Positive locoregional lymph nodes as detected by prostate-specific membrane antigen-positron emission tomography (PSMA-PET) scans OR ≤ 5 local lymph nodes on MRI can be enrolled.
Participants must have undergone a PSMA-PET (CT or MRI) scan within 3 months prior to screening as part of the standard of care (SOC).
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

Критерии исключения

Participants are excluded from the study if any of the following criteria apply:

Prior treatment for participant's prostate cancer.

\- Exception: Participants intended for enrollment in cohort B may have received an oral GnRH antagonist up to 3 months prior to the start of screening.

Any evidence of metastases outside of the surgical resection field identified by conventional imaging or PSMA-PET scans.
Confirmed history or current autoimmune disease or other diseases resulting in permanent immunosuppression or requiring permanent immunosuppressive therapy.
Participants with symptoms and/or clinical signs and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection within 7 days prior to the first dose of study treatment:

\- Participant has known active infection requiring antibiotic treatment. Upon completion of antibiotics and resolution of symptoms, the participant may be considered eligible for the study from an infection standpoint.

Recent history of arterial or venous thrombosis (eg, stroke, transient ischemic attack, pulmonary embolism, or deep vein thrombosis) within 6 and 3 months prior to the first dose of study treatment, respectively. Note: Participants with a history of venous thrombosis must be on stable anti-coagulation.
Myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association ≥ class II) within 12 months of first dose of xaluritamig with the exception of ischemia or non-ST segment elevation myocardial infarction controlled with stent placement more than 6 months prior to first dose of xaluritamig.
Requirement for chronic systemic corticosteroid therapy unless stopped (with adequate tapering) within 7 days prior to dosing.
Currently receiving treatment in another investigational device or drug study, or less than 4 weeks (since ending treatment on another investigational device or drug study\[ies\]). Other investigational procedures and participation in observational research studies while participating in this study are excluded with the exception of investigational scans.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет